Sakaue et al

# 1 Tissue-specific enhancer-gene maps from multimodal single-cell data

# 2 identify causal disease alleles

3

Saori Sakaue<sup>1,2,3</sup>, Kathryn Weinand<sup>1,2,3,4</sup>, Kushal K. Dey<sup>3,5</sup>, Karthik Jagadeesh<sup>3,5</sup>, Masahiro
Kanai<sup>3,6,7,8</sup>, Gerald F. M. Watts<sup>9</sup>, Zhu Zhu<sup>9</sup>, Accelerating Medicines Partnership® RA/SLE
Program and Network, Michael B. Brenner<sup>9</sup>, Andrew McDavid<sup>10</sup>, Laura T. Donlin<sup>11,12</sup>, Kevin
Wei<sup>9</sup>, Alkes L. Price<sup>3,5,13</sup>, Soumya Raychaudhuri<sup>1,2,3,4,14,\*</sup>

- Center for Data Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
   USA
- Divisions of Genetics and Rheumatology, Department of Medicine, Brigham and Women's
   Hospital, Harvard Medical School, Boston, MA, USA
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,
   MA, USA
- 14 4. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- 15 5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 16 6. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA,
   USA
- Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA,
   USA
- Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and
   Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Biostatistics and Computational Biology, University of Rochester Medical Center,
   Rochester, NY, USA
- 25 11. Hospital for Special Surgery, New York, NY, USA
- 26 12. Weill Cornell Medicine, New York, NY, USA
  27 13. Department of Biostatistics, Harvard T. H. C
  - 13. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA
- 28 14. Centre for Genetics and Genomics Versus Arthritis, University of Manchester, Manchester, UK
- 29
- 30 \*Address correspondence to:
- 31 Soumya Raychaudhuri
- 32 77 Avenue Louis Pasteur, Harvard New Research Building, Suite 250D
- 33 Boston, MA 02446, USA.
- 34 soumya@broadinstitute.org
- 35 617-525-4484 (tel); 617-525-4488 (fax)
- 36

Sakaue et al

# 37 Abstract

38 Translating genome-wide association study (GWAS) loci into causal variants and genes 39 requires accurate cell-type-specific enhancer-gene maps from disease-relevant tissues. 40 Building enhancer-gene maps is essential but challenging with current experimental methods in 41 primary human tissues. We developed a new non-parametric statistical method, SCENT 42 (Single-Cell ENhancer Target gene mapping) which models association between enhancer 43 chromatin accessibility and gene expression in single-cell multimodal RNA-seg and ATAC-seg 44 data. We applied SCENT to 9 multimodal datasets including > 120,000 single cells and created 45 23 cell-type-specific enhancer-gene maps. These maps were highly enriched for causal 46 variants in eQTLs and GWAS for 1,143 diseases and traits. We identified likely causal genes for 47 both common and rare diseases. In addition, we were able to link somatic mutation hotspots to 48 target genes. We demonstrate that application of SCENT to multimodal data from 49 disease-relevant human tissue enables the scalable construction of accurate cell-type-specific 50 enhancer-gene maps, essential for defining variant function.

### Sakaue et al

### 52 Main

### 53 Introduction

54 Genome-wide association studies (GWAS) have comprehensively mapped loci for human diseases<sup>1-4</sup>. These loci harbor untapped insights about causal mechanisms that can point to 55 novel therapeutics<sup>2,5</sup>. However, only rarely are we able to define causal variants or their target 56 57 genes. Of the hundreds of associated variants that may be present in a single locus, only one or a few may be causal; others are associated since they tag causal variants<sup>2,6,7</sup>. Moreover, causal 58 59 genes may also be challenging to determine, since causal variants lie in non-coding regions in 90% of the time<sup>8-10</sup>, may regulate distant genes<sup>11-13</sup>, and may employ context-specific 60 regulatory mechanisms<sup>14–17</sup>. 61

62 To define causal variants and genes, previous studies have used both statistical and experimental approaches. Statistical fine-mapping<sup>18-23</sup> can narrow the set of candidate causal 63 variants, and is more effective when genetic studies include diverse ancestral backgrounds with 64 different allele frequencies and linkage disequilibrium structures (LD)<sup>24-28</sup>. However, these 65 approaches alone are seldom able to identify true causal variants with confidence<sup>7,23,29–32</sup>. To 66 67 define causal genes, previous studies have built enhancer-gene maps, that can be used to prioritize causal variants in enhancers and link causal variants to genes they regulate. These 68 maps often require large-scale epigenetic and transcriptomic atlases (e.g., Roadmap<sup>33</sup>, 69 BLUEPRINT<sup>34</sup>, and ENCODE<sup>35</sup>). By using these atlases, enhancer-gene maps have been built 70 71 by correlating epigenetic activity (i.e., enhancer activity; e.g., histone mark ChIP-seq and bulk ATAC-seq) with gene expression (e.g., RNA-seq)<sup>36,37</sup>, by combining epigenetic activity and 72 probability of physical contact with the gene<sup>38,39</sup>, or by integrating multiple linking strategies to 73

### Sakaue et al

create composite scores <sup>40</sup>. However, current methods largely use bulk tissues or cell lines. Bulk data potentially (i) cannot be easily applied to rare cell populations (ii) obscures the cell-type-specific nature of gene regulation and (iii) requires hundreds of experimentally characterized samples, necessitating consortium-level efforts. While perturbation experiments (e.g., CRISPR interference<sup>41</sup> or base editing<sup>42</sup>) can point to causal links between enhancers and genes, they are difficult to scale because they require the development of cell- or tissue-type specific experimental protocols <sup>43</sup>.

81 Advances in single-cell technologies offer new opportunities for building cell-type specific 82 enhancer-gene maps. Multimodal protocols now enable joint capture of epigenetic activity by 83 ATAC-seq alongside early transcriptional activity with nuclear RNA-seq<sup>44-48</sup>. These methods 84 are easily applied at scale to cells in human primary tissues without disaggregation, making it possible to easily query many samples from disease-relevant tissues. Gene-enhancer maps 85 86 can be built from this data if links between open chromatin and genes can be accurately 87 established. Since each observation is at a cell-level resolution, statistical power should exceed 88 bulk-tissue-based methods. However, the sparse and non-parametric nature of RNA-seg and 89 ATAC-seq in single-cell experiments makes confident identification of these links challenging. 90 To date, most methods use linear regression models to link enhancers and genes (e.g., ArchR<sup>49</sup> and Signac<sup>50</sup>) despite these sparse and non-parametric features or only utilize 91 92 co-accessibility of regulatory regions from ATAC-seq but not gene expression data from sc-RNA-seq (e.g., Cicero<sup>51</sup>). These previous methods have not widely demonstrated efficacy 93 94 in practice for fine-mapping of causal variants and genes in complex traits.

# Sakaue et al

95	In this context, we developed Single-Cell Enhancer Target gene mapping (SCENT), to
96	accurately map enhancer-gene pairs where an enhancer's activity (i.e. peak accessibility) is
97	associated with gene expression across individual single cells. We use Poisson regression and
98	non-parametric bootstrapping <sup>52</sup> to account for the sparsity and non-parametric distributions. We
99	predicted that peaks with gene associations identified by SCENT are more likely to be
100	functionally important. We apply SCENT to 9 multimodal datasets to build 23 cell-type specific
101	enhancer-gene maps. We show that SCENT enhancers are highly enriched in statistically
102	fine-mapped putative causal variants for eQTL and GWAS. We use SCENT enhancer-gene
103	map to define causal variants, genes, and cell types in common and rare disease loci and
104	somatic mutation hotspots, which has not been previously demonstrated by conventional
105	enhancer-gene mapping based on bulk-tissues.

106

### 107 Results

#### 108 Overview of SCENT


To identify (1) active *cis*-regulatory regions and (2) their target genes (3) in a given cell type, we leveraged single-cell multimodal datasets. SCENT accurately identifies significant association between chromatin accessibility of regulatory regions (i.e., peaks) from ATAC-seq and gene expression from RNA-seq across individual single cells (**Figure 1a**). Those associations can be used for prioritizing (1) putative causal variants if they are in regulatory regions that are associated with expression of a gene, (2) putative causal genes if they are associated with the identified regulatory region and (3) the critical cell types based on which map the relevant

### Sakaue et al

116 association is identified in. We assessed whether binarized chromatin accessibility in each of 117 the ATAC peaks is associated with expression counts for each gene in *cis* (<500kb from gene 118 body), testing one peak-gene pair at a time in each cell type (see **Methods**). We tested each 119 cell type separately to capture cell-type-specific gene regulation and to avoid spurious 120 peak-gene associations due to gene co-regulation across cell types.

Since both RNA-seg and ATAC-seg data are generally sparse<sup>50,53–56</sup>, we used Poisson 121 122 regression to model the effect of chromatin accessibility on gene expression accounting for 123 donor effects and cell-level factors capturing data guality, such as pesssrcentage of 124 mitochondrial reads. However, gene expression counts are highly variable across genes 125 (Figure 1b; Supplementary Figure 1a). Genes that are highly expressed and dispersed might 126 inflate association test statistics. This inflation was even apparent in data where we permuted 127 cell barcodes to disrupt any underlying association between ATAC and RNA profiles 128 (Supplementary Figure 1b). Common analytical statistical models (e.g., linear, negative 129 binomial and Poisson regression) all demonstrated inflated statistics (Supplementary Figure 130 1c-e). Therefore, to accurately estimate the error and significance of the effect of each 131 peak-gene pair, we implemented bootstrapping framework (i.e., resampling cells with 132 replacement: see **Methods**). This resulted in well-calibrated statistics with appropriate type I 133 error (Supplementary Figure 1f). For each accessible chromatin peak and gene expression in 134 each cell type, SCENT estimates an effect size, reflecting the strength of the regulatory effect, 135 and sign, reflecting enhancing versus silencing effects.

## Sakaue et al



136

Figure 1. Schematic overview of SCENT and SCENT enhancer-gene pairs across 9 137 single-cell multimodal datasets. a. SCENT identifies (1) active *cis*-regulatory regions and (2) 138 139 their target genes in (3) a specific cell type. Those SCENT results can be used to define causal variants, genes, and cell types for GWAS loci. b. SCENT models association between 140 141 chromatin accessibility from ATAC-seg and gene expression from RNA-seg across individual 142 cells in a given cell type. c. 9 single-cell datasets on which we applied SCENT to create 23 143 cell-type-specific enhancer-gene map. The cells in each dataset are described in UMAP 144 embeddings from RNA-seg and colored by cell types.

### Sakaue et al

#### 145 Discovery of cell-type-specific SCENT enhancer-gene links

146 We obtained a total of nine single-cell multimodal datasets from diverse human tissues 147 representing 13 cell-types (immune-related, hematopoietic, neuronal, and pituitary). Since we 148 are interested in rheumatoid arthritis and other autoimmune diseases, we created a 149 disease-relevant inflammatory tissue dataset by obtaining inflamed synovial tissues from ten 150 rheumatoid arthritis (RA) and two osteoarthritis (OA) patients (arthritis-tissue dataset;  $n_{donor} =$ 151 12). Applying stringent QC to these multimodal data, we obtained information on 30,893 cells 152 (see Methods). In addition, we obtained eight public data sets with 129,672 cells. In total we had data from 160,565 cells <sup>46,57-61</sup>. We analyzed 16,621 genes and 1,193,842 open chromatin 153 154 peaks in cis after QC (4,753,521 peak-gene pairs; Figure 1c, Supplementary Table 1). After 155 clustering cells and annotating them with cell labels, we applied SCENT individually to each of 156 the cell types with  $n_{cells}$  > 500 within each dataset to construct 23 enhancer-gene maps. SCENT 157 identified 87,648 cell-type-specific peak-gene links (false discovery rate (FDR) < 10%, Figure 158 2a, Supplementary Figure 2). Each gene had variable number of associated peaks in *cis* 159 (from 0 to 97, mean = 4.13, **Supplementary Figure 3a**).

To assess replicability of SCENT peak-gene links across datasets, we used arthritis-tissue dataset, which had the largest number of significant peak-gene pairs as a stringent discovery dataset. We compared the effects from the arthritis-tissue dataset in the same cell-type with those from other datasets (B cell, T/NK cell and myeloid cell; **Supplementary Table 2a;** see **Methods**). Despite different tissue contexts, we confirmed high directional concordance of the effect of chromatin accessibility on gene expression for

# Sakaue et al

166	peak-gene pairs significant in both datasets (mean Pearson $r = 0.62$ of effect sizes, 99% mean
167	concordance across all the datasets: Supplementary Figure 3b). For comparison, we tested
168	two popular linear parametric single-cell multimodal methods, $Arch R^{56}$ or Signac <sup>50</sup> . When
169	comparing with the same discovery and replication data (i.e., arthritis-tissue dataset as a
170	discovery and public PBMC as a replication), we noted lower directional concordance and effect
171	correlation in these previous methods than in SCENT (55)(mean Pearson's $r = 0.31$ , 62% mean
172	directional concordance in ArchR and $r = 0.24$ , 98% mean directional concordance in Signac;
173	Supplementary Table 2b and c). These results argue that SCENT can more reproducibly
174	detect enhancer-gene links compared with previous parametric methods for single-cell
175	multimodal data.

# Sakaue et al

177




Figure 2. SCENT identified functionally active and evolutionary conserved *cis*-regulatory
 regions from single-cell multimodal data.

180 **a**. The number of significant gene-peak pairs discovered by SCENT with FDR < 10%. Each dot represents the number of significant gene-peak pairs in a given cell type in a dataset (y-axis) as 181 182 a function of the number of cells in each cell type in a dataset (x-axis), colored by the dataset. b. The effect size (beta) of chromatin accessibility on the gene expression from Poisson 183 184 regression (y-axis). Each dot is a significant gene-peak pair and plotted against the distance 185 between the peak and the transcription start site (TSS) of the gene, colored as a density plot. c. 186 The mean effect size (beta) of chromatin accessibility on the gene expression in arthritis-tissue 187 dataset within each bin of TSS distance. Left; all significant gene-peak links. Right; SCENT 188 peaks within enhancers identified using chromHMM in immune-related tissues. d. Mean 189 phastCons score difference ( phastCons score) between each annotated region and all 190 *cis*-regulatory non-coding regions. We show the phastCons score for exonic regions (purple) 191 as a reference, and for SCENT (green) and all *cis*-ATAC peaks (yellow) enhancers in each 192 multimodal dataset.

### Sakaue et al

To assess if peaks (i.e., *cis*-regulatory regions) identified through SCENT were functional, we examined if (1) they co-localized with conventional *cis*-regulatory annotation, (2) the effect of peaks on expression was greater for closer peak-gene pairs, (3) SCENT peaks had high sequence conservation, and (4) peak-gene connections were more likely to be validated experimentally.

First, we tested how many of the SCENT peaks overlapped with an ENCODE cCRE<sup>62</sup>, a conventional *cis*-regulatory annotation defined by bulk-based epigenomic datasets. We observed that 98.0% of the SCENT peaks overlapped with ENCODE cCRE on average, compared to 23.3% of random *cis*-regions matched for size and 89.0% of non-SCENT peaks

202 (Supplementary Figure 3c).

203 Second, we examined the strength and direction of enhance-gene links, hypothesizing 204 that stronger links would be more proximal to the transcription start site (TSS) of target genes. We observed that the regression coefficient  $\beta_{peak}$  (the effect size of peak accessibility on gene 205 206 expression) becomes larger and more positive as the SCENT *cis*-regulatory elements (peaks) 207 get closer to the TSS (Figure 2b and Figure 2c, left panel), consistent with previous observations<sup>56,63</sup>. We annotated *cis*-regulatory regions identified by SCENT with 18-state 208 chromHMM results from 41 immune-related samples in ENCODE consortium<sup>37</sup>. When we 209 210 subset peaks to those within enhancer annotations, we observed a clearer decay in effect size 211 as a function of TSS distance (Figure 2c, right panel).

212 Third, we assessed whether SCENT peaks had higher sequence conversation across 213 species. We reasoned that SCENT captures functionally important and thus evolutionary

### Sakaue et al

214 conserved regions. The evolutionary conserved regulatory regions are known to be enriched for complex trait heritability<sup>64</sup>. We used evolutionary conservation metric, phastCons<sup>65</sup> to assess 215 216 sequence conservation at SCENT peaks. As expected, exonic regions were much more 217 evolutionary conserved than all non-coding *cis*-region (mean  $\Delta$  phastCons score = 0.38, paired t-test  $P < 10^{-323}$ ; Figure 2d, purple). The SCENT regulatory regions were also conserved 218 219 relative to non-coding *cis*-regions (mean  $\Delta$  phastCons score = 0.13, paired t-test P = 4.2 x10<sup>-42</sup> 220 in arthritis-tissue dataset; **Figure 2d**, green). In contrast, the  $\Delta$  phastCons score between all 221 *cis*-ATAC peaks and all non-coding *cis*-region was more modest (mean  $\Delta$  phastCons score = 0.092, paired t-test  $P = 8.7 \times 10^{-27}$  in arthritis-tissue dataset; Figure 2d, yellow). To test if the 222 223 higher conservation in SCENT peaks were driven by their proximity to TSS, we assessed  $\Delta$ 224 phastCons score between SCENT peaks and non-SCENT peaks with matching peaks on TSS 225 distance. SCENT peaks had significantly higher conservation scores than the non-SCENT peaks when we matched on TSS distance (mean  $\Delta$  phastCons score = 0.034,  $P = 4.7 \times 10^{-4}$  in 226 227 arthritis-tissue dataset; Supplementary Figure 3d; see Methods). The higher sequence 228 conservation suggested the functional importance of SCENT regulatory regions not solely 229 driven by TSS proximity.

Finally, we tested whether the target genes from SCENT were enriched for experimentally confirmed enhancer-gene links. We used Nasser et al.<sup>39</sup> CRISPR-Flow FISH results which included 278 positive enhancer-gene connections where perturbation decreased connections, and 5,470 negative connections. We observed that the SCENT peaks were > 4-fold enriched relative to non-SCENT peaks for positive connections (4.5X, Fisher's exact

### Sakaue et al

235  $P=1.8\times10^{-9}$ , arthritis-tissue dataset and 4.5X,  $P=1.0\times10^{-8}$  in public PBMC dataset; **Methods**, 236 **Supplementary Table 3**).

237 We anticipate that the genes with the largest number of SCENT peaks are likely to be 238 the most constraint and least tolerant to loss of function mutations. The genes with the most 239 SCENT peaks per gene included FOSB (n = 97), JUNB (n = 95), and RUNX1 (n = 77), critical 240 and highly conserved transcription factors. We used mutational constraint metrics based on the 241 absence of deleterious variants within human populations (i.e., the probability of being loss-of-function intolerant (pLI)<sup>66</sup> and the loss-of-function observed/expected upper bound 242 fraction (LOEUF)<sup>67</sup>). We observed that the normalized number of SCENT cis-regulatory 243 244 elements per gene is strongly associated with mean constraint score for the gene (beta = 0.37,  $P = 4.9 \times 10^{-90}$  for pLI where higher score indicates more constraint, and beta = -0.35. P =245 -0.35x10<sup>-106</sup> for LOEUF where lower score indicates more constraint; Supplementary Figure 246 247 4a and 4b, respectively). Previous results have shown that genes with many regulatory regions 248 based on bulk-epigenomic data had been enriched for loss-of-function intolerant genes<sup>68</sup>. We 249 were able to replicate the same trend by using the single-cell multimodal datasets and SCENT. 250


251 Enrichment of eQTL putative causal variants in SCENT peaks

We sought to examine whether the SCENT peaks are likely to harbor statistically fine-mapped putative causal variants for expression quantitative loci (eQTL). We analyzed tissue-specific eQTL fine-mapping results from GTEx consortium across 49 tissues<sup>69</sup>. We used statistical fine-mapping results (posterior inclusion probability [PIP] > 0.2) to define putative causal

### Sakaue et al

256 variants. We then tested enrichment statistics within ATAC peaks or SCENT peaks (see 257 Methods). Unsurprisingly, all the accessible regions defined by ATAC-seq in *cis*-regions were 258 modestly enriched in fine-mapped variants by 2.7X (yellow, Figure 3a). However, SCENT 259 peaks were more strikingly enriched in fine-mapped variants by 9.6X on average across all 260 datasets (green, Figure 3a). Using more stringent PIP threshold cutoffs (0.5 and 0.7) to define 261 putative causal variants resulted in even stronger enrichments (Supplementary Figure 5). 262 Since many SCENT peaks are close to TSS regions, we considered whether this 263 enrichment might be driven by TSS proximity (Figure 2c, Supplementary Figure 6a). To test 264 this, we matched each of the SCENT peak-gene pairs to one non-SCENT peak-gene pair that 265 had the most similar TSS distance (Supplementary Figure 6b). We compared the 266 fine-mapped variant enrichment between those two sets of peak-gene pairs with matched TSS 267 distance. We observed that SCENT peaks consistently had higher enrichment in all analyzed 268 datasets (Supplementary Figure 6c) than TSS-distance-matched non-SCENT peaks (e.g., 269 12.3X in SCENT vs. 9.64X in distance-matched non-SCENT in arthritis-tissue dataset). This 270 suggests that SCENT has additional information in identifying biologically important 271 cis-regulatory regions beyond TSS distance.

# Sakaue et al



272 273

73 Figure 3. SCENT enhancers are enriched in causal variants of eQTL and GWAS.

274 a. The mean causal variant enrichment for eQTL within SCENT peaks or all ATAC-seq peaks in each of the 9 single-cell datasets. The bars indicate 95% confidence intervals by bootstrapping 275 276 genes. b. Comparison of the mean causal variant enrichment for eQTL (y-axis) between 277 SCENT (green), ArchR (pink), and Signac (purple) as a function of the number of significant 278 peak-gene pairs at each threshold of significance. The bars indicate 95% confidence intervals 279 by bootstrapping genes. The ArchR results with > 100,000 peak-gene linkages are omitted, and 280 full results are in Supplementary Figure 6d. c and d. The mean causal variant enrichment for 281 GWAS within SCENT enhancers (green), all cis-ATAC peaks (vellow), ENCODE cCREs (pink), 282 EpiMap enhancers across all groups (red) and ABC enhancers across all samples (blue). 283 GWAS results were based on FinnGen (c) and UK Biobank (d). The bars indicate 95% 284 confidence intervals by bootstrapping traits. e. The mean causal variant enrichment for 285 FinnGen GWAS within intersection of SCENT enhancers and caQTL enhancers at each 286 threshold of significance. The bars indicate 95% confidence intervals by bootstrapping traits.

### Sakaue et al

287 We next compared the enrichment for eQTL causal variants in SCENT peaks to peaks identified by linear parametric methods, ArchR<sup>56</sup> and Signac<sup>50</sup> using myeloid cells in the 288 289 arthritis-tissue dataset. ArchR and Signac peaks had substantially lower causal variant 290 enrichment for eQTL in blood (1.4X and 9.3X, respectively) compared to SCENT peaks (74.1X) 291 in arthritis-tissue dataset. By varying the thresholds to define significant peak-gene associations 292 (correlation r in ArchR and FDR in SCENT), we assessed the number of peak-gene pairs and 293 the causal variant enrichment for eQTLs within these peaks (Figure 3b and Supplementary 294 Figure 6d). Indeed, SCENT peaks consistently demonstrated higher causal variant enrichment 295 than ArchR peaks and Signac peaks.

SCENT can detect *cis*-regulatory regions in a cell-type-specific manner. We created cell-type-specific enhancer-gene maps in four major cell types with > 5,000 cells across datasets; for each cell type we took the union of per-cell-type SCENT enhancers across all datasets. We observed that the cell-type-specific SCENT enhancers (e.g., SCENT B cell peaks) were most enriched in putative causal eQTL variants within relevant samples in GTEx (e.g., EBV-transformed lymphocytes; **Supplementary Figure 6e**).

These results suggest that SCENT can prioritize regulatory elements harboring putative causal eQTL variants in a cell-type-specific manner, with higher precision than the previous single-cell based method.

305

306 Enrichment of GWAS causal variants in SCENT enhancers

### Sakaue et al

307 Given that the combination of SCENT and multimodal data from disease-relevant tissues can 308 be used to guickly build disease-specific enhancer-gene maps, we sought to examine whether 309 SCENT peaks can be used for the more difficult task of prioritizing disease causal variants. To 310 identify candidate causal variants (PIP>0.2), we used fine-mapping results from complex trait loci from GWAS in two large-scale biobanks (FinnGen<sup>70</sup> [1,046 disease traits] and UK 311 Biobank<sup>71</sup> [35 binary traits and 59 quantitative traits])<sup>28</sup>. We defined enrichment statistics for 312 313 GWAS causal variants within SCENT enhancers (see Methods). The SCENT enhancers were 314 strikingly enriched in causal GWAS variants in FinnGen (31.6X on average; 1046 traits; Figure 315 3c and Supplementary Figure 7a) and UK Biobank (73.2X on average; 94 traits; Figure 3d 316 and Supplementary Figure 7b). This enrichment was again much larger than all cis-ATAC 317 peaks (12.8X in FinnGen and 38.8X in UK Biobank). Moreover, the target genes of causal 318 variants for autoimmune diseases (AID) identified by SCENT enhancer-gene map in 319 immune-related cell types had higher fraction (10.8%) of know genes implicated in Mendelian disorders of immune dysregulation  $(n_{\text{gene}} = 550)^{72,73}$  than SCENT enhancer-gene map in 320 321 fibroblast (3.8%; Supplementary Figure 7c).

We compared SCENT to other alternative genome annotations and enhancer-gene maps that have recently emerged. Causal variant enrichment in SCENT was much higher than the conventional bulk-based annotations such as ENCODE cCREs (13.9X in FinnGen and 46.5X in UK Biobank), ABC (16.3X in FinnGen and 53.3X in UK Biobank) and EpiMap, (12.9X in FinnGen and 40.6X in UK Biobank; **Figure 3c** and **3d**, **Supplementary Figure 7a** and **b**). We varied thresholds to assess recall and precision tradeoffs (FDR in SCENT, ABC score in

### Sakaue et al

328 ABC model and EpiMap correlation score in EpiMap) for identifying causal GWAS variants 329 (Supplementary Figure 8a). We constructed SCENT from 9 datasets with only 28 samples, 330 substantially less than the 833 samples used to construct EpiMap and 131 samples for the ABC 331 model. Despite this, SCENT peaks consistently demonstrated higher enrichment of causal 332 GWAS variants at a similar number of identified peak-gene linkages than ABC model and 333 EpiMap. A more stringent PIP threshold (0.5 and 0.7) to define putative causal variants further 334 increased the enrichment statistics while maintaining the higher enrichment in SCENT than bulk 335 methods (Supplementary Figure 8b). We tested whether causal genes are being identified by 336 examining a set of known genes implicated in Mendelian disorders of immune dysregulation. 337 We observed that the target genes for AID identified by SCENT enhancer-gene map in 338 immune-related cell types had higher fraction (10.8%) of implicated known Mendelian genes <sup>72,73</sup> than EpiMap (8.6%) and ABC model (4.4%) enhancer-gene map (Supplementary Figure 339 340 7c). These results demonstrate the power SCENT achieved by accurately modeling association 341 between chromatin accessibility and gene expression at the single-cell resolution.

We hypothesized that disease-causal variants prioritized by SCENT would likely modulate chromatin accessibility (e.g., transcription factor binding affinity). If so, the intersection of the SCENT enhancers and chromatin accessibility quantitative trait loci (caQTL) could further enrich the causal GWAS variants<sup>74–77</sup>. To test this hypothesis, we used single-cell ATAC-seq samples with genotype ( $n_{donor} = 17$ ; arthritis-tissue dataset) from the same tissue and performed caQTL mapping by leveraging allele-specific (AS) chromatin accessibility (binomial test followed by meta-analysis across donors) or by combining AS with inter-individual differences

Sakaue et al

(RASQUAL<sup>78</sup>: see Methods). We then defined caQTL ATAC peaks with variable thresholds 349 350 and intersected them with the SCENT enhancers. We calculated the causal GWAS variant 351 enrichment within these intersected regions. We observed drastically higher enrichment of 352 causal variants as we used more stringent threshold in defining caQTL peaks, reaching as high 353 as 333-fold enrichment (Figure 3e). This suggested that SCENT efficiently prioritized causal 354 GWAS variants in part by capturing regulatory regions of which chromatin accessibility is 355 perturbed by genetic variants and modulates gene expression. SCENT demonstrated a 356 potential to further enrich causal variants by using caQTLs if the multimodal data has matched 357 genotype data.

358

#### 359 Defining mechanisms of GWAS loci by SCENT


We finally sought to use SCENT enhancer-gene links to define causal mechanisms of complex trait GWAS. We used the fine-mapped variants from GWASs (FinnGen, UK Biobank traits and GWAS fine-mapping results of rheumatoid arthritis (RA)<sup>26</sup>, inflammatory bowel disease<sup>29</sup> and type 1 diabetes (T1D)<sup>79</sup>). SCENT linked 4,124 putative causal variants (PIP > 0.1) to their potential target genes across 1,143 traits in total (**Supplementary Table 4**).

We first focus on autoimmune loci, given that our current SCENT tracks are largely derived from immune cell types and inflammatory tissues. We prioritized a single well fine-mapped variant rs72928038 (PIP > 0.3) at 6q15 locus in multiple autoimmune diseases (RA, T1D, atopic dermatitis and hypothyroidism), within the T-cell-specific SCENT enhancer (T cells in Public PBMC datasets and Dogma-seq control and stimulated T cells; **Figure 4a**). This

Sakaue et al

- 370 enhancer was linked to BACH2, which was also the closest gene to this fine-mapped variant.
- 371 Notably, base-editing in T cells has confirmed that this variant affects BACH2 expression<sup>80</sup>.
- 372 Moreover, editing of this variant into CD8 T cells skewed naive T cells toward effector T cell
- 373 fates<sup>80</sup>.
- 374

# Sakaue et al



375

376 Figure 4. SCENT defined causal variants and genes in complex trait GWAS.

**a**. Rs72928038 at *BACH2* locus was prioritized by T-cell-specific SCENT enhancer-gene map, being for RA, T1D, Atopic dermatitis and hypothyroidism. The top four panels are GWAS

# Sakaue et al

379 regional plots, with x-axis representing the position of each genetic variant. The color of the dots represent LD  $r^2$  from the prioritized variant (highlighted by light blue stripe). ATAC-seq and 380 381 SCENT tracks represent aggregated ATAC-seq tracks (top) and SCENT peaks (bottom with 382 grey stripes) in each cell type (public PBMC dataset for immune cell types and arthritis-tissue 383 dataset for fibroblast). An arrow head indicates the SCENT peak overlapping with fine-mapped 384 variant. b. Rs35944082 for RA and T1D was prioritized and connected to RBPJ by long-range 385 interaction from T-cell- and fibroblast- SCENT enhancer-gene map using inflamed synovium in 386 arthritis-tissue dataset. The top two panels are GWAS regional plots similarly to panel a. 387 ATAC-seg and SCENT tracks are shown similarly to panel a, but using both public PBMC and 388 arthritis-tissue datasets. c. Rs11031006 was prioritized and connected to FSHB for multiple gynecological traits by using pituitary-derived single-cell multimodal dataset. The top four 389 390 panels are GWAS regional plots similarly to panel a. ATAC-seq and SCENT tracks are shown 391 similarly to panel a, and include tracks from pituitary dataset. There were no SCENT peaks in 392 cell types except for pituitary. d. ATAC-seq and SCENT tracks for IL10RA locus, where 393 non-coding ClinVar variants (grey dots) colocalized with T-cell SCENT track. e. ATAC-seg and 394 SCENT tracks for CXCR4 locus, where somatic mutation hotspot for leukemia colocalized with 395 T-cell and myeloid-cell SCENT tracks.

### Sakaue et al

396 Another locus for RA and T1D at chr 4p15.2 harbored 21 candidate variants, each with 397 low PIPs (< 0.14). SCENT prioritized a single variant rs35944082 in T cells and fibroblasts only 398 within the arthritis-tissue dataset from inflamed synovial tissue (Figure 4b). SCENT linked this 399 variant to RBPJ, which was the 3rd closest gene to this variant located 235kb away. This 400 variant-gene link was supported by a physical contact from promotor-capture Hi-C contact data measured in hematopoietic cells<sup>81</sup>. RBPJ (recombination signal binding protein for 401 402 immunoglobulin kappa J region) is a transcription factor critical for NOTCH signaling, which has 403 been implicated in RA tissue inflammation through functional studies<sup>82,83</sup>. Rbpj knockdown in mice resulted in abnormal T cell differentiation and disrupted regulatory T cell phenotype<sup>84,85</sup>. 404 405 consistent with a plausible role gene in autoimmune diseases. Intriguingly, we observed no 406 SCENT peaks in T cells from PBMC or blood to prioritize causal variants at this locus. This 407 linkage was not present in EpiMap. ABC map prioritized another variant, rs7441808 at this 408 locus and linked it non-specifically to 16 genes including RBPJ, making it difficult to define the 409 true causal gene.

In a final example, we highlight the value of using SCENT to build enhancer-gene maps from disease-critical tissues. We examined the enhancer-gene map produced from single-cell multimodal pituitary data<sup>61</sup> to assess the 11p14.1 locus for multiple gynecological traits (endometriosis, menorrhagia, ovarian cyst and age at menopause). Our map connected rs11031006 to *FSHB* (follicle stimulating hormone subunit beta) (**Figure 4c**), which is specifically expressed in the pituitary<sup>69,86</sup> and enables ovarian folliculogenesis to the antral follicle stage<sup>87</sup>. Rare genetic variants within *FSHB* are known to cause autosomal recessive

### Sakaue et al

hypogonadotropic hypogonadism<sup>88</sup>. However, the other multimodal datasets and bulk-based
methods (ABC model and EpiMap) were unable to prioritize and connect this variant to *FSHB*. *FSHB* example showed the potential of SCENT for defining causal variants and genes by being
applied to disease-relevant tissues.

421

# 422 Mendelian-disease variants and somatic mutations in cancer within SCENT enhancers

423 Having established the SCENT's utility in defining causal variants and genes in complex 424 diseases, we examined rare non-coding genetic variants causing Mendelian diseases. 425 Currently, causal mutations and genes can only be identified in ~30-40% of patients with Mendelian diseases <sup>89-91</sup>. Consequently, many variants identified in case individuals are 426 427 annotated as variants of uncertain significance (VUS). The VUS annotation is especially 428 challenging for non-coding variants. We asked whether our SCENT enhancers overlapped with clinically reported non-benign non-coding variants by ClinVar<sup>92</sup> (400,300 variants in total). The 429 430 SCENT enhancers harbored 2.0 times ClinVar variants on average than all the ATAC regions 431 with the same genomic length across all the datasets we investigated (Supplementary Figure 432 9). This density of ClinVar variants was 3.2 times and 12 times on average larger than that in 433 ENCODE cCREs and of all non-coding regions, respectively. We thus defined 3.724 target 434 genes for 33,618 non-coding ClinVar variants by SCENT in total (Supplementary Table 5). As 435 illustrative examples, we found 40 non-coding variants linked to LDLR gene causing familial 436 hypercholesterolemia 1<sup>92</sup>, 3 non-coding variants linked to *IL10RA* causing autosomal recessive

### Sakaue et al

437 early-onset inflammatory bowel disease 28 (Figure 4d)<sup>93</sup>, and an intronic variant rs1591491477
438 linked to *ATM* gene causing hereditary cancer-predisposing syndrome<sup>92</sup>.

439 Finally, we used SCENT to connect non-coding somatic mutation hotspots to target 440 genes. Recently, somatic mutation analyses across the entire cancer genome revealed possible driver non-coding events<sup>94</sup>. Among 372 non-coding somatic hotspots in 19 cancer 441 442 types, SCENT enhancers included 193 cancer-mutation hotspot pairs (Supplementary Table 443 6). SCENT enhancer-gene linkage successfully linked those hotspots to known driver genes 444 (e.g., BACH2, BCL6, BCR, CXCR4 (Figure 4e), and IRF8 in leukemia). In some instances, 445 SCENT nominated different target genes for those mutation hotspots from those based on ABC 446 model used in the original study. For example, SCENT connected a somatic mutation hotspot in 447 leukemia at chr14:105568663-106851785 to IGHA1 (Immunoglobulin Heavy Constant Alpha 1) 448 which might be more biologically relevant than ADAM6 nominated by ABC model. These results 449 implicate broad applicability of SCENT for annotating all types of human variations in 450 non-coding regions.

451

### 452 Augmenting SCENT enhancer-gene maps with more samples

While the recall for enhancer-gene maps defined by SCENT was lower than that by bulk-tissue-based methods, we felt that this might be a function of current limited sample sizes. We wanted to assess if the addition of more cells into SCENT might lead to the higher recall for enhancer-gene maps while retaining the precision. To assess this, we downsampled our multimodal single cell dataset. We observed that the number of significant gene-peak pairs

### Sakaue et al

458	increased linearly to the number of cells per cell type in a given dataset, suggesting that SCENT
459	will be even better powered as the size of sc-multimodal datasets increases (Supplementary
460	Figure 10). We considered the possibility that enhancer-gene maps with greater numbers of
461	cells might capture spurious associations; if this was the case, we would expect more
462	long-range associations, which are more likely to be false positives with greater cell numbers. In
463	contrast, we observed that shorter-range and longer-range associations were both equivalently
464	represented as we added additional cells, suggesting the robustness of our discovery.

- 465
- 466

#### 467 **Discussion**

468 In this study, we presented a novel statistical method, SCENT, to create a cell-type-specific 469 enhancer-gene map by using single-cell multimodal data. Single-cell RNA-seg and ATAC-seg 470 are both sparse and have variable count distributions, which requires non-parametric 471 bootstrapping to connect chromatin accessibility with gene expression. The SCENT model 472 demonstrated well-controlled type I error, outperforming commonly used statistical models 473 which showed inflated statistics. SCENT mapped enhancers that showed strikingly high 474 enrichment for putative causal variants in eQTLs and GWASs and outperformed previous methods analyzing single-cell multimodal data (e.g., ArchR<sup>49</sup> and Signac<sup>50</sup>). Despite using 475 476 substantially lower number of samples (28 from 9 datasets in total), enhancers defined by SCENT had equivalent or even higher enrichment for causal variants than bulk-tissue-based 477

### Sakaue et al

478 methods with more than 100 samples (e.g., EpiMap and ABC model), by modeling single-cell
479 level observations instead of obscuring them into sample-level association.

480 As potential limitations, first, our enhancer-gene maps had relatively fewer enhancers 481 identified compared to other resources (Figure 2a). However, downsampling experiments 482 showed a clear linear relationship between the number of cells per cell type per dataset and the 483 number of significant SCENT peak-gene links. It follows that SCENT applied to larger datasets 484 from a diverse set of tissues will further expand the current enhancer-gene map. In contrast, 485 bulk-tissue-based enhancer-gene map might have an upper limit of discovery by the number of 486 samples generated by each consortium (e.g., ENCODE). Second, SCENT focuses on gene 487 cis-regulatory mechanisms to fine-map disease causal alleles, while there could be other 488 causal mechanisms that explain disease heritability, such as alleles that act through 489 trans-regulatory effects, splicing effects, or post-transcriptional effects<sup>95</sup>.

490 We argue that the real utility of SCENT is that it enables the rapid construction of 491 disease-tissue-relevant enhancer-gene maps. Multimodal single cell data can be easily 492 obtained from a wide range of primary human tissues. Since these assays query nuclear 493 material, data can be obtained without disaggregating tissues. Hence, the data is likely robust 494 to the effects of disaggregation which is employed for assays that need intact cells from tissue. 495 Therefore, it is possible to build relevant tissue-specific enhancer-gene maps that are 496 necessary to understand the causal mechanisms of common diseases from GWAS, rare 497 diseases from mapping Mendelian diseases, and somatic non-coding mutations in cancers. For

# Sakaue et al

498	example, understanding the FSHB locus in gynecological traits specifically required a pituitary
499	map, and RBPJ locus in RA specifically required a synovial tissue map.
500	In summary, our method SCENT is a robust, versatile method to efficiently define causal
501	variants and genes in human diseases and will fill the gap in the current enhancer-gene map
502	built from genomic data in bulk tissues.
503	
504	Data Availability
505	The publicly available datasets were downloaded via Gene Expression Ombibus (accession
506	codes: GSE140203, GSE156478, GSE178707, GSE193240, GSE178453) or web repository
507	(https://www.10xgenomics.com/resources/datasets?query=&page=1&configure%5Bfacets%5D
508	%5B0%5D=chemistryVersionAndThroughput&configure%5Bfacets%5D%5B1%5D=pipeline.ve
509	rsion&configure%5BhitsPerPage%5D=500&menu%5Bproducts.name%5D=Single%20Cell%2
510	0Multiome%20ATAC%20%2B%20Gene%20Expression,
511	https://openproblems.bio/neurips_docs/data/dataset/). The raw data for arthritis-tissue dataset
512	(single-cell multimodal RNA/ATAC-seq and single-cell ATAC-seq) will be publicly available
513	before the acceptance of this manuscript.
514	
515	Code Availability
516	The computational scripts related to this manuscript are available at
517	https://github.com/immunogenomics/SCENT.
518	

### Sakaue et al

#### 519 Methods

### 520 Data and sample in arthritis-tissue dataset

521 This study was performed in accordance with protocols approved by the Brigham and Women's 522 Hospital and the Hospital for Special Surgery institutional review boards. Synovial tissue from 523 patients with RA and OA were collected from synovectomy or arthroplasty procedures followed by cryopreservation as previously described<sup>96</sup>. RA samples with high levels of lymphocyte 524 525 infiltration (as scored by a pathologist on histologic sections) were identified as "inflamed" and 526 used for downstream analysis. Next, cryopreserved synovial tissue fragments were dissociated by a mechanical and enzymatic digestion<sup>96</sup>, followed by flow sorting to enrich for live synovial 527 528 cells. For each tissue sample, 15,000 viable cells were isolated and lysed to extract nuclei 529 according to manufacturer protocol (10X Genomics). Joint sc-RNA- and sc-ATAC-seg libraries 530 were prepared using the 10x Genomics Single Cell Multiome ATAC + Gene Expression kit 531 according to manufacturer's instructions. Libraries were sequenced with paired-end 150-bp 532 reads on an Illumina Novaseg to a target depth of 20,000 read pairs per nuclei for mRNA 533 libraries and 25,000 read pairs per nucleus for the ATAC libraries. Demultiplexed scRNA-seq 534 fastq files were inputted into the Cell Ranger ARC pipeline (version 2.0.0) from 10x Genomics 535 to generate barcoded count matrix of gene expression. For ATAC-seq, we trimmed adaptor and 536 primer sequences and mapped the trimmed reads to the hg38 genome by BWA-MEM with 537 default parameters. To deduplicate reads from PCR amplification bias within a cell while 538 keeping reads originating from the same positions but from different cells, we used in-house 539 scripts (manuscript in preparation).

#### Sakaue et al

540

541 Uniform processing of single-cell multimodal datasets

542 In addition to our arthritis-tissue multimodal dataset, we downloaded all publicly available 543 multimodal RNA-seq/ATAC-seq datasets from adult human tissues ( $n_{\text{dataset}} = 9$ , as of April 544 2022). We processed these downloaded count matrices of gene expression and ATAC data. 545 Briefly, we applied QC to both the nuclear RNA data and the ATAC data based on RNA counts, 546 ATAC fragments, nucleosome signal, and TSS enrichment (Supplementary Table 7). We only 547 kept cells that had passed QC in both RNA-seg and ATAC-seg. Then to identify open chromatin 548 regions (peaks), we used macs2 to call open chromatin peaks using post-QC ATAC-seq data. 549 We thus obtained count matrices of gene expression and ATAC peaks with corresponding cell 550 barcodes. Gene expression counts were normalized using the NormalizeData function 551 (Seurat<sup>97</sup>), scaled using the ScaleData function (Seurat), and batch corrected using Harmony<sup>98</sup>. 552 We visualized the cells in two low-dimensional embeddings with UMAP by using 20 553 batch-corrected principal components from these normalized gene expression matrices (Figure 554 1c). When original cell labels are provided by the authors, we used those labels to obtain broad 555 cell type categories. When they are not available, we performed reference-query mapping by 556 Seurat and PBMC reference object to define broad cell type labels. ATAC peak matrix was 557 binarized to have 1 if a count is > 0 and 0 otherwise.

558

559 SCENT method

### Sakaue et al

560 We defined *cis*-peaks as any peaks whose center is within the window +/-500 bp from the target 561 gene's TSS. We modeled the association between peak's binarized accessibility and the target 562 gene's expression with Poisson distribution:

### $E_i \sim Poisson(\lambda_i)$

$$log(\lambda_i) = \beta_0 + \beta_{peak} X_{peak} + \beta_{\%mito} X_{\%mito} + \beta_{nUMI} X_{nUMI} + \beta_{batch} X_{batch}$$

where  $E_i$  is the observed expression count of *i*th gene, and  $\lambda_i$  is the expected count under 563 564 Poisson distribution.  $\beta_{peak}$  indicates the effect of chromatin accessibility of a peak on i th 565 gene expression.  $\beta_{\% mito}$ ,  $\beta_{n IIMI}$ , and  $\beta_{batch}$  each represents the effect of covariates, 566 percentage of mitochondrial reads per cell as a mesure of cell quality, the number of UMIs in 567 the cell, and the batch, respectively. To assess significance of  $\beta_{peak}$ , we used bootstrapping 568 procedures, where we resampled cells with replacement in each procedure and estimate 569  $\beta'_{peak}$  within those cells. To reduce computational burden, we adaptively increased the number of from at least 100 and up to 10,000, depending on the significance of  $\beta_{peak}$  in each chunk of 570 571 bootstrapping trials. To avoid spurious associations from rare ATAC peak and rare gene 572 expression, we QCed cis-peak-gene pairs we test so that both peak and gene should have 573 been expressed in at least 5% of the cells we analyze. We finally defined a set of significant 574 peak-gene pairs for each cell type based on FDR (Benjamini & Hochberg correction).

575 When we tested the calibration of statistics from SCENT or other regression strategies 576 (**Supplementary Figure 1**), we used null dataset where we randomly permuted cell labels in 577 the ATAC-seq and ran the regression model we tested.

578

### Sakaue et al

#### 579 ArchR peak2gene and Signac LinkPeaks method

We analyzed arthritis-tissue dataset with ArchR<sup>49</sup> and Signac<sup>50</sup> for single-cell multimodal data. 580 581 which both have a function to define peak-gene linkages. In brief, ArchR takes multimodal data 582 and creates low-overlapping aggregates of single cells based on k-nearest neighbor graph. Then it correlates peak accessibility with gene expression by Pearson correlation of aggregated 583 584 and log2-normalized peak count and gene count. Signac computes the Pearson correlation 585 coefficient r (corSparse function in R) for each gene and for each peak within 500kb of the gene 586 TSS. Signac then compares the observed correlation coefficient with an expected correlation 587 coefficient for each peak given the GC content, accessibility, and length of the peak. Signac 588 defines P value for each gene-peak links from the z score based on this comparison. We ran 589 both methods on arthritis-tissue dataset with default parameters. We output statistics for all 590 peak-gene pairs we tested without any cut-off for correlation r or P values. We used FDR in the 591 output from ArchR software, or computed FDR using P values in the output from Signac 592 software by Benjamini & Hochberg correction. We defined significant peak-gene linkages as 593 those with FDR < 0.10, and used varying correlation r to assess the precision and recall in the 594 causal variant enrichment analysis (see later sections in Method).

595

### 596 *Replication across datasets*

597 Since we have the same immune-related cell types across different multimodal datasets, we 598 evaluated the concordance of enhancer-gene map in a discovery dataset (arthritis-tissue 599 dataset) when compared with other replication datasets including immune-related cell types

Sakaue et al

600 (Public PBMC, NeurIPS, SHARE-seq and NEAT-seq datasets). To this end, we used most 601 stringent FDR threshold for defining an enhancer-gene map in arthritis-tissue dataset (FDR < 602 1%). We then used more lenient threshold for defining an enhancer-gene map in replication 603 datasets (FDR < 10%), which is a similar strategy used in assessing replication in GWAS. For 604 each cell type and for each replication dataset, we took the intersection of enhancer-gene links 605 defined as significant in both datasets. We assessed the directional concordance (i.e., 606 concordance of the sign of  $\beta_{peak}$ ) and the Pearson's correlation r of  $\beta_{peak}$  between the 607 discovery and the replication for these peak-gene pairs. For the largest replication dataset of 608 Public PBMC, we performed the same analysis for enhancer-gene map from ArchR and Signac 609 software.

610

### 611 Conservation score analysis

612 To compare the evolutional conservation across species between our annotated peaks and the other peaks, we used phastCons<sup>65</sup> score. We downloaded the phastCons score for multiple 613 614 alignments of 99 vertebrate genomes from 615 https://hgdownload.cse.ucsc.edu/goldenpath/hg19/phastCons100way/. We lifted them over to 616 GRCh38 by LiftOver software. We used SCENT results for arthritis-tissue. Public PBMC and 617 NeurIPS for conservation score analysis as representative datasets with the largest numbers of 618 cells. Because each gene should have variable functional importance and conservation, we 619 assessed each gene separately. For each gene, we took (1) an annotation of interest for the 620 gene and (2) all cis-non-coding regions (< 500kb from a gene), and computed the mean

### Sakaue et al

phastCons score of each of two sets of the peaks. As annotations to be tested, we used a. exonic regions of the gene, b. SCENT peaks for the gene, and c. all ATAC peaks in cis-regions from the gene (< 500 kb). Then, we took the difference between two mean differences ( $\Delta$  phastCons score), and computed the mean differences across all the genes (mean  $\Delta$  phastCons score) as follows.

mean 
$$\Delta$$
 phastCons score =  $\frac{1}{n_{gene}} \sum_{gene} \overline{(phastCons_{g,in\_annot} - \overline{phastCons}_{g,non-coding})}$ 

By bootstrapping the genes, we calculated the 95% CI of the mean  $\Delta$  phastCons score. If this metric is positive, that indicates that the annotated regions are more conserved than non-coding regions.

We also calculated similar ∆ phastCons score by comparing the SCENT peaks with
 TSS-distance-matched non-SCENT peaks in each dataset.

mean Δ phastCons score

$$=\frac{1}{n_{gene}}\sum_{gene}\overline{(phastCons}_{g,peak\_in\_SCENT} - \overline{phastCons}_{g,peak\_non\_SCENT\_matched})$$

By bootstrapping the genes, we again calculated the 95% CI of the mean  $\Delta$  phastCons score. If this metric is positive, that indicates that SCENT peaks are more conserved than TSS-distance-matched non-SCENT peaks.

634

# 635 Construction of a set of TSS-matched non-SCENT peaks

To assess the effect of TSS distance when comparing SCENT peaks with non-SCENT peaks, we matched each one of the SCENT peak-gene pairs to one non-SCENT peak-gene pair, where the peak had the most similar TSS distance to the same gene among all the ATAC peaks

#### Sakaue et al

639 in *cis* in each of the dataset. We confirmed that the resulting TSS-distance-matched 640 non-SCENT peak-gene pairs demonstrated the similar distributions of TSS distance when 641 compared with the SCENT peak-gene pairs (**Supplementary Figure 5b**).

642

### 643 Gene's constraint and the number of significant SCENT peaks for a gene

644 We sought to investigate the relationship between the number of significant SCENT peaks for 645 each gene and the gene's evolutionary constraint. We used pLI and LOEUF as metrics for the 646 gene's loss-of-function intolerance within human population. We downloaded both pLI and 647 LOEUF scores from gnomAD browser (https://gnomad.broadinstitute.org/downloads). We 648 inverse-normal transformed the raw number of significant SCENT peaks for each gene, since 649 the raw number of significant SCENT peaks for each gene is rightly skewed (Supplementary 650 Figure 3a). We performed linear regression between the normalized number of significant 651 SCENT peaks and pLI or LOEUF score with accounting for gene length, which could be potential confounding factor for pLI and LOEUF<sup>66,67</sup>. 652

653

#### 654 Validation with CRISPR-Flow FISH results

To validate our SCENT enhancer-gene links, we used published CRISPR-Flow FISH experiments as potential ground-truth positive enhancer element-gene links and negative enhancer element-gene links. We downloaded the experimental results from the **Supplementary Table 5** of original publication<sup>39</sup>. We used "Perturbation Target" as candidate enhancer elements. We defined 283 positive enhancer element-gene links when they are

### Sakaue et al

660 "TRUE" for "Regulated" column (i.e., the element-gene pair is significant and the effect size is 661 negative) and 5,472 negative enhancer element-gene links when they are "FALSE" for 662 "Regulated" column. We lifted them over to GRCh38 and obtained final sets of 278 positive 663 links and 5,470 negative links.

We used two most powered datasets, arthritis-tissue and Public PBMC datasets. For each dataset, we used "bedtools intersect" to categorize SCENT peak-gene links and non-SCENT ATAC peak-gene pairs into either CRISPR-positive or CRISPR-negative groups, based on whether these peaks overlapped with positive or negative CRISPR-Flow FISH links for the same gene (**Supplementary Table 3**). We finally performed two-sided Fisher's exact test to assess the enrichment of CRISPR-positive links within SCENT peak-gene links in each dataset.

671

#### 672 Cell-type-specific SCENT tracks and aggregated SCENT tracks

For cell types with more than 5,000 cells across datasets, we concatenated SCENT peak-gene linkages across all the datasets to create cell-type-specific SCENT tracks. We collected a set of SCENT peak-gene linkages for the same cell type and used "bedtools merge" function (for each gene) to obtain a union of SCENT peaks for each gene. Similarly, we created aggregated SCENT tracks across all the cell types and all datasets. We collected all sets of SCENT peak-gene linkages and used "bedtools merge" function (for each gene) to obtain a union of SCENT tracks across all the cell types and all datasets. We collected all sets of SCENT peak-gene linkages and used "bedtools merge" function (for each gene) to obtain a union of SCENT peaks for each gene across all the cell types and all datasets.

680

## Sakaue et al

#### 681 Causal variant enrichment analysis using eQTLs

682 We defined a causal enrichment for eQTL within SCENT enhancers and other annotations by 683 using statistically fine-mapped variant-gene combinations from GTEx. We used publicly available statistics analyzed by CAVIAR software<sup>20</sup>, and selected variants with PIP > 0.2 as 684 putatively causal (fine-mapped) variants for primary analyses. For the primary enrichment 685 686 analysis, we aggregated fine-mapped variants from all the 49 tissues. For cell-type-specific 687 SCENT enrichment analysis (Supplementary Figure 6e), we used fine-mapped variants from 688 each tissue separately. We intersected these putatively causal variants with our annotation 689 (SCENT peaks, ArchR peaks or Signac peaks). We then retained any variants which the linking 690 method (SCENT, ArchR and Signac) connected to the same gene as GTEx phenotype gene.

$$\# causal_var_in_annot_{gene_i} / \sum common_var_in_annot_{gene_i}$$

$$Enrichment_{gene_{i}} = \frac{}{\# causal\_var_{gene_{i}}/\sum common\_var\_in\_cis_{gene_{i}}}$$

691

$$Overall\_Enrichment = \frac{1}{n} \sum_{i=1}^{n} Enrichment_{gene\_i}$$

For each gene *i* (expression phenotype), we divided the number of putatively causal variants within an annotation normalized by the number of common variants within an annotation by the number of all causal variants for gene *i* normalized by the number of all common variants within cis-region from for gene *i*. To calculate common variants within annotation or within locus, we used 1000 Genomes Project genotype. We selected any variants with minor allele

#### Sakaue et al

697 frequency > 1% in European population as a set of common variants to be intersected with 698 each annotation. To derive *Overall Enrichment* score, we took the mean across all the genes. 699 To have further insights into precision and recall and compare against ArchR peak2gene 700 and Signac LinkPeaks functions, we varied the threshold for defining a set of significant 701 peak-gene linkages in each software (i.e., FDR in SCENT {0.50, 0.30, 0.20, 0.10, 0.05, 0.02}, 702 Peason's correlation r {any, 0, 0.1, 0.3, 0.5, 0.7} in ArchR, and correlation socre {any, 0, 0.05, 703 0.1, 0.15} in Signac). We then used each set of peak-gene linkages to re-calculate causal 704 variant enrichment *Overall Enrichment* score (Figure 3b). 705 We also assessed the impact of PIP threshold in defining a set of statistically

fine-mapped variants on the causal variant enrichment analysis. To do so, we re-defined the set of putative causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and re-computed the calculate causal variant enrichment  $Overall\_Enrichment$  score.

709

### 710 GWAS fine-mapping results

We used GWAS fine-mapping results in FinnGen release  $6^{70}$  upon registration and publicly available GWAS fine-mapping results in UK Biobank<sup>71</sup> (https://www.finucanelab.org/data). For FinnGen traits, we downloaded all the fine-mapping results by SuSIE software<sup>22</sup> and systematically selected any traits with case count > 1,000. We then selected non-coding fine-mapped loci which did not include any non-synonymous or splicing variants with PIP > 0.5. We thus analyzed 1,046 traits and 5,753 loci in total after QC. For UK Biobank, we analyzed the fine-mapping results by SuSIE software for all 94 traits including binary and quantitative traits.

Sakaue et al

Since the genomic coordinates for the UK Biobank fine-mapping results were hg19, we lifted them over to GRCh38 by using LiftOVer software. We again selected non-coding fine-mapped loci which did not include any non-synonymous or splicing variants with PIP > 0.5. We thus analyzed 7,274 loci in total after QC.

We analyzed three additional autoimmune GWAS fine-mapping results for  $RA^{26}$ ,  $T1D^{79}$ , and  $IBD^{29}$ , given our special interest in immune-mediated traits. We similarly selected non-coding fine-mapped loci which did not include any non-synonymous or splicing variants with PIP > 0.5, and lifted the results over to GRCh38 by using LiftOVer software. We defined 117 loci for RA, 77 loci for T1D and 86 loci for IBD.

- 727
- 728 Causal variant enrichment analysis using GWASs

We defined a causal enrichment for GWAS within SCENT enhancers and other annotations by using statistically fine-mapped variants from FinnGen<sup>70</sup> and UK Biobank<sup>71</sup> which we described in the previous section. We selected variants with PIP > 0.2 as putatively causal variants for primary analyses.

$$= \frac{\# causal\_var\_in\_annot_{trait\_i}}{\# causal\_var\_trait\_i} / \sum common\_var\_in\_annot_{trait\_i}}$$

733

$$Overall\_Enrichment = \frac{1}{n} \sum_{i=1}^{n} Enrichment_{trait\_i}$$

### Sakaue et al

For each trait *i*, we divided the number of putatively causal variants within an annotation (across all loci for trait *i*) normalized by the number of common variants within an annotation by the number of all causal variants for trait *i* normalized by the number of all common variants within all significant loci analyzed for the trait *i*. To calculate common variants within annotation or within locus, we again used 1000 Genomes Project variants with minor allele frequency > 1% in European population. To derive *Overall\_Enrichment* score, we took the mean across all the traits.

741

# 742 Comparison with bulk-tissue-based regulatory annotation and enhancer-gene maps

743 We downloaded per-group EpiMap enhancer-gene links from 744 https://personal.broadinstitute.org/cboix/epimap/links/pergroup/. We lifted the aenomic 745 coordinates to GRCh38 by using LiftOver software. When we assessed aggregated EpiMap 746 enhancer-gene links across all the groups, we used "bedtools merge" function for each gene to 747 create a union of all enhancer-gene links. To benchmark the precision and recall, we used 748 EpiMap correlation scores to define variable sets of enhancer-gene links from EpiMap based on 749 the threshold of EpiMap correlation score.

750 We downloaded ABC predictions in 131 cell types and tissues from 751 ftp://ftp.broadinstitute.org/outgoing/lincRNA/ABC/AllPredictions.AvgHiC.ABC0.015.minus150.F 752 orABCPaperV3.txt.gz. We lifted the genomic coordinates to GRCh38 by using LiftOver software. 753 When we assessed cell-type-specific ABC model with SCENT enhancers, we aggregated cell 754 lines or cell types to be corresponding with our cell types (B cell, T cell, Myeloid cells, and

40

#### Sakaue et al

755	fibroblasts). When we assessed aggregated ABC enhancer-gene links across all the groups,
756	we used "bedtools merge" function for each gene to create a union of all enhancer-gene links.
757	To benchmark the precision and recall, we used ABC scores to define variable sets of
758	enhancer-gene links from ABC model based on the threshold of ABC score.

- To assess precision and recall and compare against bulk-tissue based methods (i.e., EpiMap and ABC model), we used sets of significant peak-gene linkages in each method with varying thresholds (i.e., FDR in SCENT {0.5, 0.3, 0.2, 0.1, 0.05, 0.02}, EpiMap score {0, 0.4, 0.8, 0.9} in EpiMap, and ABC score {0, 0.05, 0.1, 0.2} for ABC model). We then used each set of peak-gene linkages to re-calculate causal variant enrichment for GWAS (**Figure 3d**).
- We also assessed the impact of PIP threshold in defining a set of statistically fine-mapped variants on the causal variant enrichment analysis. To do so, we re-defined the set of putative causal variants with more stringent PIP thresholds (PIP > 0.5 and PIP > 0.7), and re-computed the calculate causal variant enrichment *Overall Enrichment* score.
- 768
- 769 caQTL analysis using scATAC-seq samples with genotype

We used independent arthritis-tissue dataset with single-cell unimodal ATAC-seq data with genotype (n = 17, manuscript in preparation) to define chromatin accessibility QTLs (caQTLs). We used two methods, binomial test and RASQUAL. Briefly, we genotyped donors by using Illumina Multi-Ethnic Genotyping Array. We performed quality control of genotype by sample call rate > 0.99, variant call rate > 0.99, minor allele frequency > 0.01, and  $P_{HWE} > 1.0 \times 10^{-6}$ . We performed haplotype phasing with SHAPEIT2 software<sup>99</sup> and performed whole-genome

### Sakaue et al

imputation by using minimac3 software<sup>100</sup> with a reference panel of 1000 Genomes Project phase  $3^{101}$ . After imputation, we selected variants with imputation *Rsq* > 0.7 as post-imputation QC. We next created a merged bam file of ATAC-seq for each donor and each cell type by aggregating all the reads. Using the imputed genotype for each donor and aggregated bam files for each donor and cell type, we applied WASP<sup>102</sup> to correct any bias in read mapping toward reference alleles to accurately quantify allelic imbalance. We thus created a bias-corrected bam files for each donor and cell type.

783 For binomial tests, we ran ASEReadCounter module in GATK software<sup>103</sup> using the 784 bias-corrected bam files as input to quantify allelic imbalance in heterozygous sites with read 785 count > 4 within ATAC peak counts. We first performed one-sided binomial tests in each donor, 786 and meta-analyzed the statistics across donors by Fisher's method if multiple donors shared 787 the same heterozygous site. For RASQUAL, we created a VCF file containing both genotype 788 dosage and allelic imbalance from ASEReadCounter. We guantified the read coverage for each peak and for each donor by "bedtools coverage" function. We created a peak by donor matrix 789 790 with read coverage. We QCed samples with log(total mapped fragments) fewer than mean -791 2SD across samples in each cell type. We QCed peaks so that at least two individuals have any 792 fragments for the peak. We then ran RASQUAL software with the inter-individual differences in 793 ATAC peak counts (in a peak by donor matrix) and intra-individual allelic imbalance (in VCF), 794 with accounting for chromatin accessibility PCs (the first N components whose explained 795 variances are greater than those from permutation result), 3 genotype PCs, sample site and sex 796 as covariates. RASQUAL output chi-squared statistics and P values. We computed FDR from

Sakaue et al

797	these raw P values by Benjamini & Hochberg correction on local multiple test burden (i.e., the
798	number of cis-SNPs in the region). To correct for genome-wide multiple testing, we ran the
799	RASQUAL with random permutation, where the relationship between sample labels and the
800	count matrix was broken. Thus, we derived $q$ values for each candidate caQTL.
801	We finally intersected these peaks with significant caQTL effect in each significance
802	threshold with SCENT peaks and assessed causal variants enrichment within these peaks for
803	GWAS as explained in the previous sections.
804	
805	ClinVar analysis
806	We downloaded the latest clinically reported variant list registered at ClinVar from
807	https://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh38/clinvar.vcf.gz. We then screened the
808	variants to exclude (1) exonic variants and (2) variants categorized as "benign". We defined the
809	ClinVar variant density as the number of the non-coding and non-benign variants within each
810	annotation x 1,000 divided by the total length (bp) of each annotation.

811

# 812 Somatic mutation analysis

We used a list of somatic mutation hotspot in Supplementary Table 2-20 of the original publication<sup>94</sup>. We lifted the genomic coordinates to GRCh38 by using LifOver software. We then intersected the non-coding somatic mutation hotspots with our cell-type-specific SCENT peaks. We compared the intersected elements' target genes by SCENT with the "Annotate\_Gene" column from the original publication.

43

#### Sakaue et al

818

## 819 Downsampling experiments

- To evaluate the effect of cell numbers on the statistical power in detecting significant SCENT enhancer-gene linkages, we performed downsampling experiments in fibroblast (the most abundant cell type in arthritis-tissue dataset,  $n_{cell} = 9,905$ ). We randomly samples cells ( $n_{cell} =$ 500, 1000, 2500, 5000, and 7500). We then applied SCENT to each of the subset groups of cells and defined significant peak-gene links with FDR < 10%. We counted the number of significant peak-gene links in each of the subset groups of cells, and annotated peaks based on the distance to the TSS to the target gene.
- 827

# 828 **References**

- Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of
   SNP-trait associations. *Nucleic Acids Res.* 2014;42(Database issue):D1001-6.
- 831 doi:10.1093/nar/gkt1229
- Visscher PM, Wray NR, Zhang Q, et al. 10 Years of GWAS Discovery: Biology, Function,
  and Translation. *Am J Hum Genet*. 2017;101(1):5-22. doi:10.1016/J.AJHG.2017.06.005
- Buniello A, Macarthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published
   genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 2019;47(D1):D1005-D1012. doi:10.1093/NAR/GKY1120
- Claussnitzer M, Cho JH, Collins R, et al. A brief history of human disease genetics. *Nature* 2020 577:7789. 2020;577(7789):179-189. doi:10.1038/s41586-019-1879-7
- 839 5. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human
  840 genetics. *Nature Reviews Drug Discovery 2013 12:8*. 2013;12(8):581-594.
  841 doi:10.1038/nrd4051
- Shendure J, Findlay GM, Snyder MW. Genomic Medicine–Progress, Pitfalls, and Promise.
   *Cell.* 2019;177(1):45-57. doi:10.1016/J.CELL.2019.02.003

Sakaue et al

844 7. Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal 845 variants by statistical fine-mapping. Nature Reviews Genetics 2018 19:8. 846 2018;19(8):491-504. doi:10.1038/s41576-018-0016-z 847 8. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common 848 disease-associated variation in regulatory DNA. Science (1979). 849 2012:337(6099):1190-1195. 850 doi:10.1126/SCIENCE.1222794/SUPPL FILE/MAURANO.SM.PDF 851 9. Edwards SL, Beesley J, French JD, Dunning M. Beyond GWASs: illuminating the dark 852 road from association to function. Am J Hum Genet. 2013;93(5):779-797. 853 doi:10.1016/J.AJHG.2013.10.012 854 10. Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine 855 mapping complex trait variants. Nat Genet. 2013;45(2):124-130. doi:10.1038/ng.2504 11. 856 Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene 857 promoters. Nature 2012 489:7414, 2012:489(7414):109-113. doi:10.1038/nature11279 858 12. Smemo S, Tena JJ, Kim KH, et al. Obesity-associated variants within FTO form 859 long-range functional connections with IRX3. Nature 2014 507:7492. 860 2014;507(7492):371-375. doi:10.1038/nature13138 861 Won H, de La Torre-Ubieta L, Stein JL, et al. Chromosome conformation elucidates 13. 862 regulatory relationships in developing human brain. Nature 2016 538:7626. 863 2016;538(7626):523-527. doi:10.1038/nature19847 864 14. Strober BJ, Elorbany R, Rhodes K, et al. Dynamic genetic regulation of gene expression during cellular differentiation. Science. 2019;364(6447):1287-1290. 865 866 doi:10.1126/SCIENCE.AAW0040 867 15. Cuomo ASE, Seaton DD, McCarthy DJ, et al. Single-cell RNA-sequencing of 868 differentiating iPS cells reveals dynamic genetic effects on gene expression. Nature 869 Communications 2020 11:1. 2020;11(1):1-14. doi:10.1038/s41467-020-14457-z Zhernakova D v., Deelen P, Vermaat M, et al. Identification of context-dependent 870 16. 871 expression quantitative trait loci in whole blood. Nat Genet. 2017;49(1):139-145. 872 doi:10.1038/NG.3737 873 17. Nathan A, Asgari S, Ishigaki K, et al. Single-cell eQTL models reveal dynamic T cell state 874 dependence of disease loci. Nature 2022 606:7912. 2022;606(7912):120-128. 875 doi:10.1038/s41586-022-04713-1

## Sakaue et al

876 18. Wakefield J. A Bayesian Measure of the Probability of False Discovery in Genetic Epidemiology Studies. Am J Hum Genet. 2007;81(2):208. doi:10.1086/519024 877 878 19. Maller JB, McVean G, Byrnes J, et al. Bayesian refinement of association signals for 14 879 loci in 3 common diseases. Nat Genet. 2012;44(12):1294-1301. doi:10.1038/NG.2435 880 20. Hormozdiari F, Kostem E, Kang EY, Pasaniuc B, Eskin E. Identifying causal variants at 881 loci with multiple signals of association. Genetics. 2014;198(2):497-508. doi:10.1534/GENETICS.114.167908 882 883 21. Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: 884 efficient variable selection using summary data from genome-wide association studies. 885 Bioinformatics. 2016;32(10):1493-1501. doi:10.1093/BIOINFORMATICS/BTW018 886 22. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable 887 selection in regression, with application to genetic fine mapping. J R Stat Soc Series B Stat 888 Methodol. 2020;82(5):1273-1300. doi:10.1111/RSSB.12388 889 23. Weissbrod O, Hormozdiari F, Benner C, et al. Functionally informed fine-mapping and 890 polygenic localization of complex trait heritability. Nature Genetics 2020 52:12. 891 2020;52(12):1355-1363. doi:10.1038/s41588-020-00735-5 892 24. Wojcik GL, Graff M, Nishimura KK, et al. Genetic analyses of diverse populations 893 improves discovery for complex traits. Nature 2019 570:7762. 2019;570(7762):514-518. 894 doi:10.1038/s41586-019-1310-4 895 25. Chen MH, Raffield LM, Mousas A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell 896 Genetics in 746,667 Individuals from 5 Global Populations. Cell. 897 2020;182(5):1198-1213.e14. doi:10.1016/J.CELL.2020.06.045 898 26. Ishigaki K, Sakaue S, Terao C, et al. Trans-ancestry genome-wide association study 899 identifies novel genetic mechanisms in rheumatoid arthritis. medRxiv. 900 2021:12:2021.12.01.21267132. doi:10.1101/2021.12.01.21267132 901 27. Kichaev G, Pasaniuc B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-Mapping Studies. Am J Hum Genet. 2015:97(2):260-271. 902 903 doi:10.1016/J.AJHG.2015.06.007 904 28. Kanai M, Ulirsch JC, Karjalainen J, et al. Insights from complex trait fine-mapping across 905 diverse populations. medRxiv. Published online September 5, 906 2021:2021.09.03.21262975. doi:10.1101/2021.09.03.21262975

907	29.	Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to
908		single-variant resolution. Nature. 2017;547(7662):173-178. doi:10.1038/NATURE22969
909	30.	Farh KKH, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal
910		autoimmune disease variants. <i>Nature 2014 518:7539</i> . 2014;518(7539):337-343.
911		doi:10.1038/nature13835
912	31.	Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant
913		resolution using high-density imputation and islet-specific epigenome maps. Nature
914		Genetics 2018 50:11. 2018;50(11):1505-1513. doi:10.1038/s41588-018-0241-6
915	32.	Kichaev G, Yang WY, Lindstrom S, et al. Integrating functional data to prioritize causal
916		variants in statistical fine-mapping studies. PLoS Genet. 2014;10(10).
917		doi:10.1371/JOURNAL.PGEN.1004722
918	33.	Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis
919		of 111 reference human epigenomes. Nature 2015 518:7539. 2015;518(7539):317-330.
920		doi:10.1038/nature14248
921	34.	Chen L, Ge B, Casale FP, et al. Genetic Drivers of Epigenetic and Transcriptional
922		Variation in Human Immune Cells. Cell. 2016;167(5):1398-1414.e24.
923		doi:10.1016/j.cell.2016.10.026
924	35.	Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the
925		human genome. Nature. 2012;489(7414):57-74. doi:10.1038/NATURE11247
926	36.	Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and analysis of chromatin state
927		dynamics in nine human cell types. Nature 2011 473:7345. 2011;473(7345):43-49.
928		doi:10.1038/nature09906
929	37.	Boix CA, James BT, Park YP, Meuleman W, Kellis M. Regulatory genomic circuitry of
930		human disease loci by integrative epigenomics. Nature 2021 590:7845.
931		2021;590(7845):300-307. doi:10.1038/s41586-020-03145-z
932	38.	Fulco CP, Nasser J, Jones TR, et al. Activity-by-Contact model of enhancer-promoter
933		regulation from thousands of CRISPR perturbations. Nat Genet. 2019;51(12):1664.
934		doi:10.1038/S41588-019-0538-0
935	39.	Nasser J, Bergman DT, Fulco CP, et al. Genome-wide enhancer maps link risk variants to
936		disease genes. <i>Nature 2021 593:7858</i> . 2021;593(7858):238-243.
937		doi:10.1038/s41586-021-03446-x

- 938 40. Gazal S, Weissbrod O, Hormozdiari F, et al. Combining SNP-to-gene linking strategies to
  939 identify disease genes and assess disease omnigenicity. *Nat Genet*. 2022;54(6):827-836.
  940 doi:10.1038/S41588-022-01087-Y
- 941 41. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–Cas technologies and
  942 applications. *Nature Reviews Molecular Cell Biology 2019 20:8*. 2019;20(8):490-507.
  943 doi:10.1038/s41580-019-0131-5
- 42. Anzalone A v., Koblan LW, Liu DR. Genome editing with CRISPR–Cas nucleases, base
  editors, transposases and prime editors. *Nature Biotechnology 2020 38:7*.
  2020;38(7):824-844. doi:10.1038/s41587-020-0561-9
- 947 43. Baglaenko Y, Macfarlane D, Marson A, Nigrovic PA, Raychaudhuri S. Genome editing to
  948 define the function of risk loci and variants in rheumatic disease. *Nature Reviews*949 *Rheumatology 2021 17:8.* 2021;17(8):462-474. doi:10.1038/s41584-021-00637-8
- 44. Cao J, Cusanovich DA, Ramani V, et al. Joint profiling of chromatin accessibility and gene
  expression in thousands of single cells. *Science (1979)*. 2018;361(6409):1380-1385.
- 952 doi:10.1126/SCIENCE.AAU0730/SUPPL\_FILE/AAU0730\_TABLESS1\_S13.XLSX
- 953 45. Chen S, Lake BB, Zhang K. High-throughput sequencing of the transcriptome and
  954 chromatin accessibility in the same cell. *Nature Biotechnology 2019 37:12*.
  955 2019;37(12):1452-1457. doi:10.1038/s41587-019-0290-0
- 46. Ma S, Zhang B, LaFave LM, et al. Chromatin Potential Identified by Shared Single-Cell
  Profiling of RNA and Chromatin. *Cell*. 2020;183(4):1103-1116.e20.
- 958 doi:10.1016/J.CELL.2020.09.056
- 47. Allaway KC, Gabitto MI, Wapinski O, et al. Genetic and epigenetic coordination of cortical
  interneuron development. *Nature 2021 597:7878*. 2021;597(7878):693-697.
- 961 doi:10.1038/s41586-021-03933-1
- 962 48. Trevino AE, Müller F, Andersen J, et al. Chromatin and gene-regulatory dynamics of the
  963 developing human cerebral cortex at single-cell resolution. *Cell*.
- 964 2021;184(19):5053-5069.e23. doi:10.1016/J.CELL.2021.07.039
- 965 49. Granja JM, Corces MR, Pierce SE, et al. ArchR is a scalable software package for
  966 integrative single-cell chromatin accessibility analysis. *Nature Genetics 2021 53:3.*
- 967 2021;53(3):403-411. doi:10.1038/s41588-021-00790-6

968	50.	Stuart T, Srivastava A, Madad S, Lareau CA, Satija R. Single-cell chromatin state analysis
969		with Signac. Nature Methods 2021 18:11. 2021;18(11):1333-1341.
970		doi:10.1038/s41592-021-01282-5
971	51.	Pliner HA, Packer JS, McFaline-Figueroa JL, et al. Cicero Predicts cis-Regulatory DNA
972		Interactions from Single-Cell Chromatin Accessibility Data. Mol Cell.
973		2018;71(5):858-871.e8. doi:10.1016/J.MOLCEL.2018.06.044
974	52.	Efron B, Tibshirani RJ. An Introduction to the Bootstrap. An Introduction to the Bootstrap.
975		Published online May 14, 1994. doi:10.1201/9780429246593
976	53.	Lähnemann D, Köster J, Szczurek E, et al. Eleven grand challenges in single-cell data
977		science. Genome Biology 2020 21:1. 2020;21(1):1-35. doi:10.1186/S13059-020-1926-6
978	54.	Sarkar A, Stephens M. Separating measurement and expression models clarifies
979		confusion in single-cell RNA sequencing analysis. Nature Genetics 2021 53:6.
980		2021;53(6):770-777. doi:10.1038/s41588-021-00873-4
981	55.	Chen H, Lareau C, Andreani T, et al. Assessment of computational methods for the
982		analysis of single-cell ATAC-seq data. Genome Biol. 2019;20(1):1-25.
983		doi:10.1186/S13059-019-1854-5/FIGURES/7
984	56.	Granja JM, Klemm S, McGinnis LM, et al. Single-cell multiomic analysis identifies
985		regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology 2019
986		<i>37:12</i> . 2019;37(12):1458-1465. doi:10.1038/s41587-019-0332-7
987	57.	Luecken MD, Burkhardt DB, Cannoodt R, et al. A sandbox for prediction and integration of
988		DNA, RNA, and proteins in single cells. Proceedings of the Neural Information Processing
989		Systems Track on Datasets and Benchmarks. 2021;1. Accessed September 11, 2022.
990		https://openproblems.bio/neurips.
991	58.	Mimitou EP, Lareau CA, Chen KY, et al. Scalable, multimodal profiling of chromatin
992		accessibility, gene expression and protein levels in single cells. Nat Biotechnol.
993		2021;39(10):1246-1258. doi:10.1038/S41587-021-00927-2
994	59.	Chen AF, Parks B, Kathiria AS, Ober-Reynolds B, Goronzy JJ, Greenleaf WJ. NEAT-seq:
995		simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene
996		expression in single cells. Nature Methods 2022 19:5. 2022;19(5):547-553.
997		doi:10.1038/s41592-022-01461-y

- Meijer M, Agirre E, Kabbe M, et al. Epigenomic priming of immune genes implicates
  oligodendroglia in multiple sclerosis susceptibility. *Neuron*. 2022;110(7):1193-1210.e13.
  doi:10.1016/J.NEURON.2021.12.034
- 1001 61. Zhang Z, Zamojski M, Smith GR, et al. Single nucleus transcriptome and chromatin
  1002 accessibility of postmortem human pituitaries reveal diverse stem cell regulatory
  1003 mechanisms. *Cell Rep.* 2022;38(10). doi:10.1016/J.CELREP.2022.110467
- Abascal F, Acosta R, Addleman NJ, et al. Expanded encyclopaedias of DNA elements in
  the human and mouse genomes. *Nature 2020 583:7818*. 2020;583(7818):699-710.
  doi:10.1038/s41586-020-2493-4
- 1007 63. Westra HJ, Franke L. From genome to function by studying eQTLs. *Biochim Biophys Acta*.
  2014;1842(10):1896-1902. doi:10.1016/J.BBADIS.2014.04.024
- Hujoel MLA, Gazal S, Hormozdiari F, van de Geijn B, Price AL. Disease Heritability
  Enrichment of Regulatory Elements Is Concentrated in Elements with Ancient Sequence
  Age and Conserved Function across Species. *Am J Hum Genet*, 2019;104(4):611-624.
- 1012 doi:10.1016/j.ajhg.2019.02.008
- 1013 65. Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate,
  1014 insect, worm, and yeast genomes. *Genome Res.* 2005;15(8):1034-1050.
- 1015 doi:10.1101/GR.3715005
- 101666.Lek M, Karczewski KJ, Minikel E v., et al. Analysis of protein-coding genetic variation in101760,706 humans. Nature. 2016;536(7616):285-291. doi:10.1038/nature19057
- 101867.Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified1019from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443.
- 1020 doi:10.1038/s41586-020-2308-7
- 1021 68. Wang X, Goldstein DB. Enhancer Domains Predict Gene Pathogenicity and Inform Gene
  1022 Discovery in Complex Disease. *The American Journal of Human Genetics*.
  1023 2020;106(2):215-233. doi:10.1016/J.AJHG.2020.01.012
- 102469.Aguet F, Barbeira AN, Bonazzola R, et al. The GTEx Consortium atlas of genetic1025regulatory effects across human tissues. Science. 2020;369(6509):1318.
- 1026 doi:10.1126/SCIENCE.AAZ1776
- 1027 70. Kurki MI, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining
  1028 isolated population and national health register data. *medRxiv*. Published online March 6,
  1029 2022:2022.03.03.22271360. doi:10.1101/2022.03.03.22271360

## Sakaue et al

1030 71. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping 1031 and genomic data. Nature. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z 1032 72. Dey KK, Gazal S, van de Geijn B, et al. SNP-to-gene linking strategies reveal contributions 1033 of enhancer-related and candidate master-regulator genes to autoimmune disease. Cell 1034 Genomics. 2022;2:100145. doi:10.1016/j.xgen.2022.100145 1035 73. Freund MK, Burch KS, Shi H, et al. Phenotype-Specific Enrichment of Mendelian Disorder 1036 Genes near GWAS Regions across 62 Complex Traits. The American Journal of Human Genetics. 2018;103(4):535-552. doi:10.1016/J.AJHG.2018.08.017 1037 1038 74. Gate RE, Cheng CS, Aiden AP, et al. Genetic determinants of co-accessible chromatin 1039 regions in activated T cells across humans. Nature Genetics 2018 50:8. 1040 2018;50(8):1140-1150. doi:10.1038/s41588-018-0156-2 1041 75. Khetan S, Kursawe R, Youn A, et al. Type 2 Diabetes-Associated Genetic Variants 1042 Regulate Chromatin Accessibility in Human Islets. *Diabetes*. 2018;67(11):2466-2477. 1043 doi:10.2337/DB18-0393 1044 76. Alasoo K, Rodrigues J, Mukhopadhyay S, et al. Shared genetic effects on chromatin and 1045 gene expression indicate a role for enhancer priming in immune response. Nat Genet. 1046 2018;50(3):424. doi:10.1038/S41588-018-0046-7 1047 77. Currin KW, Erdos MR, Narisu N, et al. Genetic effects on liver chromatin accessibility 1048 identify disease regulatory variants. Am J Hum Genet. 2021;108(7):1169-1189. 1049 doi:10.1016/J.AJHG.2021.05.001 1050 78. Kumasaka N, Knights AJ, Gaffney DJ. Fine-mapping cellular QTLs with RASQUAL and 1051 ATAC-seq. Nature Genetics 2015 48:2. 2015;48(2):206-213. doi:10.1038/ng.3467 1052 79. Chiou J, Geusz RJ, Okino ML, et al. Interpreting type 1 diabetes risk with genetics and 1053 single-cell epigenomics. Nature 2021 594:7863. 2021;594(7863):398-402. 1054 doi:10.1038/s41586-021-03552-w Mouri K, Guo MH, de Boer CG, et al. Prioritization of autoimmune disease-associated 1055 80. 1056 genetic variants that perturb regulatory element activity in T cells. Nature Genetics 2022 1057 54:5. 2022;54(5):603-612. doi:10.1038/s41588-022-01056-5 1058 81. Javierre BM, Sewitz S, Cairns J, et al. Lineage-Specific Genome Architecture Links 1059 Enhancers and Non-coding Disease Variants to Target Gene Promoters. Cell. 1060 2016;167(5):1369-1384.e19. doi:10.1016/J.CELL.2016.09.037

Sakaue et al

- 1061 82. Radtke F, Fasnacht N, MacDonald HR. Notch signaling in the immune system. *Immunity*.
  1062 2010;32(1):14-27. doi:10.1016/J.IMMUNI.2010.01.004
- 1063 83. Wei K, Korsunsky I, Marshall JL, et al. Notch signalling drives synovial fibroblast identity
  and arthritis pathology. *Nature*. 2020;582(7811):259-264.

1065 doi:10.1038/S41586-020-2222-Z

- 1066 84. Delacher M, Schmidl C, Herzig Y, et al. Rbpj expression in regulatory T cells is critical for
  1067 restraining TH2 responses. *Nature Communications 2019 10:1*. 2019;10(1):1-20.
  1068 doi:10.1038/s41467-019-09276-w
- 1069 85. Blake JA, Baldarelli R, Kadin JA, Richardson JE, Smith CL, Bult CJ. Mouse Genome
  1070 Database (MGD): Knowledgebase for mouse–human comparative biology. *Nucleic Acids*
- 1071 Res. 2021;49(D1):D981. doi:10.1093/NAR/GKAA1083
- 1072 86. Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome.
  1073 Science (1979). 2015;347(6220).
- 1074 doi:10.1126/SCIENCE.1260419/SUPPL\_FILE/1260419\_UHLEN.SM.PDF
- 107587.Hillier SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell1076Endocrinol. 2001;179(1-2):39-46. doi:10.1016/S0303-7207(01)00469-5
- 1077 88. Rubinstein WS, Maglott DR, Lee JM, et al. The NIH genetic testing registry: a new,
  1078 centralized database of genetic tests to enable access to comprehensive information and
  1079 improve transparency. *Nucleic Acids Res.* 2013;41(D1):D925-D935.
- 1080 doi:10.1093/NAR/GKS1173
- 1081 89. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing
  1082 across clinical indications. *Genet Med.* 2016;18(7):696-704. doi:10.1038/GIM.2015.148
- 1083 90. Adams DR, Eng CM. Next-Generation Sequencing to Diagnose Suspected Genetic
- 1084
   Disorders. N Engl J Med. 2018;379(14):1353-1362. doi:10.1056/NEJMRA1711801
- 1085 91. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary
- 1087 individuals with neurodevelopmental disorders. *Genet Med.* 2019;21(11):2413-2421.
- 1088 doi:10.1038/S41436-019-0554-6

1086

1089 92. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations

consensus statement: exome sequencing is a first-tier clinical diagnostic test for

- and supporting evidence. *Nucleic Acids Res.* 2018;46(D1):D1062-D1067.
- 1091 doi:10.1093/NAR/GKX1153

- 1092 93. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory Bowel Disease and Mutations
  1093 Affecting the Interleukin-10 Receptor. *New England Journal of Medicine*.
- 1094 2009;361(21):2033-2045.
- 1095 doi:10.1056/NEJMOA0907206/SUPPL\_FILE/NEJM\_GLOCKER\_2033SA1.PDF
- 1096 94. Dietlein F, Wang AB, Fagre C, et al. Genome-wide analysis of somatic noncoding 1097 mutation patterns in cancer. *Science (1979)*. 2022;376(6589).
- doi:10.1126/SCIENCE.ABG5601/SUPPL\_FILE/SCIENCE.ABG5601\_MDAR\_REPRODU
   CIBILITY\_CHECKLIST.PDF
- 1100 95. Connally N, Nazeen S, Lee D, et al. The missing link between genetic association and
  1101 regulatory function. *medRxiv*. Published online October 13, 2022:2021.06.08.21258515.
  1102 doi:10.1101/2021.06.08.21258515
- 110396.Donlin LT, Rao DA, Wei K, et al. Methods for high-dimensional analysis of cells dissociated1104from cyropreserved synovial tissue. Arthritis Res Ther. 2018;20(1):1-15.
- 1105 doi:10.1186/S13075-018-1631-Y/FIGURES/6
- 1106 97. Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. *Cell*.
  1107 2019;177(7):1888-1902.e21. doi:10.1016/J.CELL.2019.05.031
- 1108 98. Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell
  1109 data with Harmony. *Nature Methods 2019 16:12*. 2019;16(12):1289-1296.
- 1110 doi:10.1038/s41592-019-0619-0
- 1111 99. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of
  1112 genomes. *Nat Methods*. 2012;9(2):179-181. doi:10.1038/nmeth.1785
- 1113 100. Das S, Forer L, Schönherr S, et al. Next-generation genotype imputation service and
  1114 methods. *Nature Genetics 2016 48:10*. 2016;48(10):1284-1287. doi:10.1038/ng.3656
- 1115 101. Gibbs RA, Boerwinkle E, Doddapaneni H, et al. A global reference for human genetic
  1116 variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393
- 1117 102. van der Auwera G, O'Connor B, Safari an OMCompany. *Genomics in the Cloud.*; 2020.
  1118 Accessed December 25, 2021.
- 1119 https://www.oreilly.com/library/view/genomics-in-the/9781491975183/
- 1120
- 1121
- 1122 Acknowledgments

Sakaue et al

1123 We would like to sincerely thank participants of this study who provided tissue samples. We 1124 thank Anika Gupta, Joyce Kang and Kaitlyn Lagattuta for their comments and helpful discussion 1125 on the manuscript. This work is supported in part by funding from the National Institutes of 1126 Health (R01AR063759, U01HG012009, UC2AR081023). S.S. was in part supported by the Uehara Memorial Foundation and The Osamu Hayaishi Memorial Scholarship. K.W. is 1127 1128 supported by a Burroughs Wellcome Fund Career Awards for Medical Scientists, a Doris Duke 1129 Charitable Foundation Clinical Scientist Development Award, and a Rheumatology Research 1130 Foundation Innovative Research Award. We would like to thank the Brigham and Women's 1131 Hospital Center for Cellular Profiling Single Cell Mulitomics Core for experimental design and 1132 protocol optimization.

1133

#### 1134 Author Contributions

1135 S.S. and S.R. conceived the work and wrote the manuscript with critical input from co-authors.

1136 S.S. and K. Weinand analyzed the arthritis-tissue dataset and S.S. analyzed publicly available

1137 datasets with help and guidance from K.K.D., K.J., M.K., A.M., A.L.P., and S.R. G.F.M.W., Z.Z.,

1138 M.B.B., L.T.D., and K.Wei provided samples and generated the arthritis-tissue dataset.

1139

## 1140 Competing Financial Interests

1141 We declare no conflict of interest for this study. S.R. is a founder for Mestag, Inc, a scientific

advisor for Rheos, Jannsen, and Pfizer, and serves as a consultant for Sanofi and Abbvie.